TScan Therapeutics, Inc.
TCRX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001783328
No open-market purchases or sales by TScan Therapeutics, Inc. insiders were filed in the last 90 days; 60 institutions reported holding it in 13F filings for Q2 2026, worth $35.1M in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding TScan Therapeutics, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Of which not filed for Q1 2025 | Q1 2025 | Change |
|---|---|---|---|---|
| Holders | 89 | 1 | 92 | +4 |
| Shares | 41.5M | 70.0K | 40.1M | −1.32M (−3.2%) |
| Value | $126.2M | $212.7K | $55.4M | −$70.6M (−56.0%) |
1 institution that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (17)
Institutions that held TScan Therapeutics, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Millennium Management LLC | 231,175 | $319.0K | 0.00% |
| Two Sigma Investments, LP | 90,201 | $124.5K | 0.00% |
| Nuveen, LLC | 69,962 | $96.5K | 0.00% |
| Two Sigma Advisers, LP | 49,000 | $67.6K | 0.00% |
| Gsa Capital Partners LLP | 41,817 | $58.0K | 0.01% |
| HSBC Holdings PLC | 35,042 | $49.4K | 0.00% |
| Bank of Montreal | 24,992 | $34.5K | 0.00% |
| Acadian Asset Management LLC | 17,782 | $24.0K | 0.00% |
| Boothbay Fund Management, LLC | 16,242 | $22.4K | 0.00% |
| Mariner, LLC | 14,580 | $20.1K | 0.00% |
| Virtu Financial LLC | 11,023 | $15.0K | 0.00% |
| Federated Hermes, Inc. | 2,182 | $3.01K | 0.00% |
| Coldstream Capital Management Inc | 555 | $766 | 0.00% |
| Point72 (DIFC) Ltd | 492 | $678 | 0.00% |
| CoreCap Advisors, LLC | 166 | $229 | 0.00% |
| True Wealth Design, LLC | 33 | $46 | 0.00% |
| EverSource Wealth Advisors, LLC | 21 | $29 | 0.00% |
Sold out (13)
Institutions that held TScan Therapeutics, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Wellington Management Group LLP | 132,895 | $404.0K |
| Woodline Partners LP | 115,866 | $352.2K |
| Dauntless Investment Group, LLC | 110,345 | $335.4K |
| LMR Partners LLP | 71,800 | $218.3K |
| Marshall Wace, LLP | 43,969 | $133.7K |
| Shay Capital LLC | 21,363 | $64.9K |
| Squarepoint Ops LLC | 19,461 | $59.2K |
| Jacobs Levy Equity Management, Inc | 18,951 | $57.6K |
| Manufacturers Life Insurance Company, The | 14,715 | $44.7K |
| Qube Research & Technologies Ltd | 14,508 | $44.1K |
| Voya Investment Management LLC | 12,786 | $38.9K |
| US Bancorp | 2,265 | $6.89K |
| Lazard Asset Management LLC | 70 | $0 |
Not filed for Q1 2025 yet (1)
Institutions that held TScan Therapeutics, Inc. at the end of Q4 2024 and haven't filed a 13F for Q1 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Nuveen Asset Management, LLC | 69,962 | $212.7K |